Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
SSI and Intercell will continue their collaboration in the field of Tuberculosis research and vaccine development with Intercell's proprietary adjuvant IC31®, and by the involvement of Sanofi Pasteur extend the activities into more advanced phases aiming to make a new TB vaccine widely available in shortest possible time.
The collaboration with Aeras Global TB Vaccine Foundation in the TB vaccine field will continue and together the parties represent the extensive range of technology and expertise necessary to solve this complex global health problem.
We are very happy that Sanofi Pasteur is now contributing all its outstanding vaccine expertise to this very promising tuberculosis vaccine program comments Intercells Chief Executive Officer Gerd Zettlmeissl. The preclinical and the Phase I clinical studies performed so far have impressively proven that our novel adjuvant IC31® will play an important role in this combined vaccine approach.
Financial details are not disclosed.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.